Drug Profile
Research programme: Chagas disease vaccines - Aeras/Baylor College of Medicine/Eisai/Sabin Vaccine Institute
Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Sabin Vaccine Institute
- Developer Aeras; Baylor College of Medicine; Eisai Co Ltd; Sabin Vaccine Institute
- Class Recombinant proteins; Vaccines
- Mechanism of Action Immunostimulants; Toll-like receptor 4 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chagas disease
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Chagas'-disease in USA (Parenteral)
- 28 Jul 2015 The Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development receive a grant from The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation for vaccine development for Chagas disease
- 15 Sep 2014 Sabin vaccine Institute, Eisai, Aeras, Baylor College of Medicine receive a grant from Global Health Innovative Technology Fund for vaccine development in Chagas disease